Company intelligence / Profile preview
Kinoxis Therapeutics
Camberwell, Victoria, Australiakinoxistherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
KNX100 has completed Phase 1 clinical trials and is advancing to Phase 2a for treating agitation associated with dementia (CARES-X study). The company also secured a partnership with Boehringer Ingelheim worth up to $273 million to develop oxytocin-targeting precision treatments.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Boehringer Ingelheim ($273 million partnership announced in May 2023)
Beyond the preview
Go deeper on Kinoxis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kinoxis Therapeutics.